Hepion Pharmaceuticals, Inc. (HEPA) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.21
↓-74% vs avg
5yr avg: 0.82
30Y Low0.2·High186.8
ROE
↓
-2058.6%
↑-264% vs avg
5yr avg: -565.0%
30Y Low-487%·High-49%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HEPA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Hepion Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $697219 | $564563 | $3M | $13M | $23M | $80M | $21M | $11M | $4M | $28M | $1.7B |
| Enterprise Value | $-1076777 | $-1209434 | $5M | $-1711468 | $-28243905 | $-10900235 | $-18782042 | $-2165045 | $2M | $22M | $1.7B |
| P/E Ratio → | -0.07 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.21 | 0.21 | — | 1.77 | 0.46 | 0.86 | 0.52 | 0.70 | 1.84 | 7.53 | 186.75 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
HEPA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
HEPA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -2058.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2058.6% | -2058.6% | -487.0% | -171.3% | -59.1% | -49.0% | -72.5% | -80.0% | -332.8% | -235.4% | -287.0% |
| ROA | -353.5% | -353.5% | -133.9% | -124.9% | -51.5% | -43.0% | -58.8% | -48.9% | -97.2% | -101.4% | -94.6% |
| ROIC | -409.9% | -409.9% | -2302.2% | — | -9983.0% | -1817.8% | -991.8% | -377.9% | -1878.7% | — | — |
| ROCE | -671.3% | -671.3% | -343.2% | -148.7% | -61.6% | -43.6% | -64.0% | -63.8% | -208.7% | -174.7% | -179.2% |
HEPA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $54066, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | — | 0.03 | 0.00 | 0.00 | 0.02 | 0.05 | 0.73 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.67 | — | -2.00 | -1.03 | -0.98 | -0.99 | -0.84 | -0.71 | -1.61 | -1.43 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -15.51 | -5118.64 | -4475.47 | -3431.91 | -645.11 | -14.00 | -43.03 | — | — |
Net cash position: cash ($2M) exceeds total debt ($54066)
HEPA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Hepion Pharmaceuticals, Inc.'s current ratio of 10.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.31x to 10.25x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.25 | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 | 9.15 | 8.94 | 1.04 | 2.33 | 4.48 |
| Quick Ratio | 10.25 | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 | 9.15 | 8.94 | 1.04 | 2.33 | 4.48 |
| Cash Ratio | 6.11 | 6.11 | 0.13 | 2.80 | 6.49 | 11.13 | 8.74 | 8.65 | 0.99 | 2.29 | 4.41 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
HEPA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Hepion Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $9M | $122894 | $79416 | $76229 | $70291 | $9677 | $2043 | $184 | $138 | $5208 |
Peer Comparison
Compare HEPA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HEPAYou | $697219 | -0.1 | — | — | — | — | -2058.6% | -409.9% | — |
 MDGL | $12B | -41.6 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 TERN | $5B | -47.3 | — | — | — | — | -29.6% | -42.2% | — |
 ELVN | $2B | -22.0 | — | — | — | — | -27.0% | -32.8% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 GNFT | $448M | 256.9 | 73.1 | 27.1 | 99.6% | 4.9% | 2.2% | 4.5% | 12.4 |
 HIMS | $7B | 50.3 | 42.7 | 89.6 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See HEPA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HEPA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HEPA vs MDGL
Side-by-side business, growth, and profitability comparison vs Madrigal Pharmaceuticals, Inc..
Start ComparisonHEPA — Frequently Asked Questions
Quick answers to the most common questions about buying HEPA stock.
What is Hepion Pharmaceuticals, Inc.'s P/E ratio?
Hepion Pharmaceuticals, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Hepion Pharmaceuticals, Inc.'s ROE?
Hepion Pharmaceuticals, Inc.'s return on equity (ROE) is -2058.6%. The historical average is -197.1%.
Is HEPA stock overvalued?
Based on historical data, Hepion Pharmaceuticals, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.